Post-treatment serum Wisteria floribunda agglutinin-positive mac-2-binding protein level is a useful predictor of hepatocellular carcinoma development after hepatitis C virus eradication.

AIMS

Recent advances of direct-acting antiviral drugs for hepatitis C virus (HCV) have dramatically improved the sustained virologic response (SVR) rate, but hepatocellular carcinoma (HCC) development rarely occurs even in patients who achieve an SVR. Wisteria floribunda agglutinin-positive mac-2-binding protein (WFA-M2BP) was recently developed as a noninvasive biomarker of liver fibrosis. However, the association between the WFA-M2BP level and HCC development after the achievement of an SVR is unclear.

METHODS AND RESULTS

We examined the association between WFA-M2BP and HCC development in 522 HCV patients who achieved an SVR (Interferon [IFN]-based therapy,  = 228; IFN-free therapy,  = 294). Multivariate analysis revealed that a high WFA-M2BP level at SVR week 24 after treatment (SVR24) (hazard ratio [HR] = 1.215,  = 0.020), low platelet counts (HR = 0.876,  = 0.037), and old age (HR = 1.073,  = 0.012) were independent risk factors for HCC development regardless of the treatment regimen. Receiver operator characteristics curve analysis revealed that a WFA-M2BP level at SVR24 of ≥1.62 cut-off index (COI) was the cut-off value for the prediction of HCC development (adjusted HR = 12.565, 95% CI 3.501-45.092,  < 0.001). The 3- and 5-year cumulative incidences of HCC were 1% and 1.6% in patients with low WFA-M2BP at SVR24 (<1.62 COI), and 4.7% and 12.5% in patients with high WFA-M2BP (≥1.62 COI) were, respectively ( < 0.001).

CONCLUSIONS

The assessment of liver fibrosis using the WFA-M2BP level at SVR24 is a useful predictor of HCC development after HCV eradication even in the IFN-free therapy era.